Physician profile
Munther Alshalabi
NPI 1033770508
$6,507.59
in general payments reported to CMS, 2019-2025
27 companies · $3,293 in 2025
The $3,293 reported for 2025 was more than what 80% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $188 · 2022: $410 · 2023: $795 · 2024: $1,823 · 2025: $3,293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,728 · Education: $181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,728.29 |
| Education | $181.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $656.34 | 2022-2023 | |
| Abbvie INC. | $610.12 | 2025 | |
| Amneal Pharmaceuticals LLC | $593.68 | 2024-2025 | Crexont, Rytary, Ongentys 50mg Capsules 30 |
| Emd Serono, INC. | $524.58 | 2024-2025 | |
| Lundbeck LLC | $448.42 | 2024-2025 | Rexulti, Vyepti |
| Eisai INC. | $360.58 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $353.40 | 2024-2025 | Austedo Xr, Austedo Xr |
| Pfizer INC. | $316.61 | 2023-2025 | |
| Lilly USA, LLC | $311.23 | 2022-2025 | Mounjaro, Kisunla, Amyvid |
| Otsuka America Pharmaceutical, INC. | $280.93 | 2024-2025 | Rexulti |
| Ucb, INC. | $273.42 | 2024-2025 | Nayzilam |
| Ani Pharmaceuticals, INC. | $258.70 | 2024-2025 | Purified Cortrophin Gel |
| Medtronic USA, INC. | $188.00 | 2019 | |
| Neurocrine Biosciences, INC. | $182.12 | 2024-2025 | Ingrezza |
| Argenx US, INC. | $178.17 | 2025 | Vyvgart Hytrulo |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $166.97 | 2024-2025 | Uplizna |
| Csl Behring | $162.01 | 2023-2025 | Hizentra |
| Astrazeneca Pharmaceuticals LP | $113.93 | 2022-2023 | Farxiga |
| Mallinckrodt Hospital Products INC. | $107.41 | 2024-2025 | Acthar |
| Axsome Therapeutics, INC. | $75.59 | 2025 | Symbravo, Auvelity |
| Exact Sciences Corporation | $71.05 | 2023 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $68.46 | 2025 | |
| Genentech USA, INC. | $58.49 | 2025 | Ocrevus Zunovo |
| Glaxosmithkline, LLC. | $57.53 | 2023 | Trelegy Ellipta, Pediarix, Shingrix |
| Ge Healthcare | $56.61 | 2025 | |
| Biogen, INC. | $20.73 | 2025 | Tysabri, Vumerity |
| Novo Nordisk INC | $12.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Munther Alshalabi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.